Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Photrexa Viscous

&times

Overview

What is Photrexa Viscous?

PHOTREXA VISCOUS (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) 0.146% and PHOTREXA (riboflavin 5’-phosphate ophthalmic solution) 0.146% are intended for topical ophthalmic administration as part of corneal collagen cross-linking with the KXL System.

PHOTREXA VISCOUS and PHOTREXA are supplied as:

PHOTREXA VISCOUS (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) 0.146% is a yellow sterile buffered viscous solution containing 1.56 mg/mL riboflavin 5’-phosphate and 20% dextran 500. The pH of the solution is approximately 7.1 and the osmolality is 301-339 mOsm/kg. Each 1 mL of solution contains 1.64 mg of riboflavin 5’-phosphate sodium (equivalent to 1.284 mg riboflavin). Riboflavin 5’-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, dextran, monobasic sodium phosphate, sodium chloride, and water for injection.

PHOTREXA (riboflavin 5’-phosphate ophthalmic solution) 0.146% is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5’-phosphate. The pH of the solution is approximately 7.1 and the osmolality is 157-177 mOsm/kg. Each 1 mL of solution contains 1.53 mg of riboflavin 5’-phosphate sodium (equivalent to 1.20 mg riboflavin). Riboflavin 5’-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monobasic sodium phosphate, sodium chloride, and water for injection.

The chemical formula for riboflavin 5’-phosphate sodium (Vitamin B2) is CHNNaOP with a molecular mass of 478.33 g/mol.

Please refer to the KXL System Operator’s Manual for a specific device description and instructions.



What does Photrexa Viscous look like?



What are the available doses of Photrexa Viscous?

What should I talk to my health care provider before I take Photrexa Viscous?

How should I use Photrexa Viscous?

PHOTREXA® VISCOUS and PHOTREXA® are indicated for use in corneal collagen cross-linking in combination with the KXL™ System for the treatment of

Using topical anesthesia, debride the epithelium to a diameter of approximately 9 mm using standard aseptic technique. Post epithelial debridement, instill 1 drop of PHOTREXA VISCOUS topically on the eye every 2 minutes for 30 minutes.

At the end of the 30 minute soaking period, examine the eye under the slit lamp for the presence of a yellow flare in the anterior chamber. If the yellow flare is not detected, instill 1 drop of PHOTREXA VISCOUS every 2 minutes for an additional 2 to 3 drops and recheck for the presence of a yellow flare. This process can be repeated as necessary.

Once the yellow flare is observed, perform ultrasound pachymetry. If corneal thickness is less than 400 microns, instill 2 drops of PHOTREXA every 5 to 10 seconds until the corneal thickness increases to at least 400 microns. Irradiation should not be performed unless this 400 micron threshold is met and the yellow flare is seen.

Irradiate the eye for 30 continuous minutes at 3mW/cm at a wavelength of 365 nm, centered over the cornea, using the KXL System as per the instructions in the KXL manual. During irradiation, continue topical instillation of PHOTREXA VISCOUS onto the eye every 2 minutes for the 30 minute irradiation period.

For topical ophthalmic use. Do not inject.

Single use PHOTREXA VISCOUS and PHOTREXA only. Discard syringe(s) after use.

PHOTREXA VISCOUS and PHOTREXA are for use with the KXL System only.

PLEASE REFER TO THE KXL OPERATOR’S MANUAL FOR SPECIFIC DEVICE INSTRUCTIONS.


What interacts with Photrexa Viscous?

Sorry No Records found


What are the warnings of Photrexa Viscous?

Sorry No Records found


What are the precautions of Photrexa Viscous?

Sorry No Records found


What are the side effects of Photrexa Viscous?

Sorry No records found


What should I look out for while using Photrexa Viscous?

None.


What might happen if I take too much Photrexa Viscous?

Sorry No Records found


How should I store and handle Photrexa Viscous?

ArraySingle-use foil pouches of PHOTREXA VISCOUS and PHOTREXA are provided in a kit of two (2): one (1) PHOTREXA VISCOUS and one (1) PHOTREXA (NDC- 25357-025-03).PHOTREXA VISCOUS (NDC 25357-022-01) and PHOTREXA (NDC 25357-023-01) are also provided in a bulk packs of ten (10), single-use foil pouches. Each foil pouch contains a 3 mL glass syringe of PHOTREXA VISCOUS or PHOTREXA contained within a Tyvek pouch.Bulk packs and kits should be stored at 15°-25°C (59°-77°F) and care should be taken to minimize exposure of the syringe to light once removed from its protective packaging. Discard syringe after use.For topical ophthalmic use.PHOTREXA VISCOUS and PHOTREXA should be used with the KXL System only.Single-use foil pouches of PHOTREXA VISCOUS and PHOTREXA are provided in a kit of two (2): one (1) PHOTREXA VISCOUS and one (1) PHOTREXA (NDC- 25357-025-03).PHOTREXA VISCOUS (NDC 25357-022-01) and PHOTREXA (NDC 25357-023-01) are also provided in a bulk packs of ten (10), single-use foil pouches. Each foil pouch contains a 3 mL glass syringe of PHOTREXA VISCOUS or PHOTREXA contained within a Tyvek pouch.Bulk packs and kits should be stored at 15°-25°C (59°-77°F) and care should be taken to minimize exposure of the syringe to light once removed from its protective packaging. Discard syringe after use.For topical ophthalmic use.PHOTREXA VISCOUS and PHOTREXA should be used with the KXL System only.Single-use foil pouches of PHOTREXA VISCOUS and PHOTREXA are provided in a kit of two (2): one (1) PHOTREXA VISCOUS and one (1) PHOTREXA (NDC- 25357-025-03).PHOTREXA VISCOUS (NDC 25357-022-01) and PHOTREXA (NDC 25357-023-01) are also provided in a bulk packs of ten (10), single-use foil pouches. Each foil pouch contains a 3 mL glass syringe of PHOTREXA VISCOUS or PHOTREXA contained within a Tyvek pouch.Bulk packs and kits should be stored at 15°-25°C (59°-77°F) and care should be taken to minimize exposure of the syringe to light once removed from its protective packaging. Discard syringe after use.For topical ophthalmic use.PHOTREXA VISCOUS and PHOTREXA should be used with the KXL System only.Single-use foil pouches of PHOTREXA VISCOUS and PHOTREXA are provided in a kit of two (2): one (1) PHOTREXA VISCOUS and one (1) PHOTREXA (NDC- 25357-025-03).PHOTREXA VISCOUS (NDC 25357-022-01) and PHOTREXA (NDC 25357-023-01) are also provided in a bulk packs of ten (10), single-use foil pouches. Each foil pouch contains a 3 mL glass syringe of PHOTREXA VISCOUS or PHOTREXA contained within a Tyvek pouch.Bulk packs and kits should be stored at 15°-25°C (59°-77°F) and care should be taken to minimize exposure of the syringe to light once removed from its protective packaging. Discard syringe after use.For topical ophthalmic use.PHOTREXA VISCOUS and PHOTREXA should be used with the KXL System only.Single-use foil pouches of PHOTREXA VISCOUS and PHOTREXA are provided in a kit of two (2): one (1) PHOTREXA VISCOUS and one (1) PHOTREXA (NDC- 25357-025-03).PHOTREXA VISCOUS (NDC 25357-022-01) and PHOTREXA (NDC 25357-023-01) are also provided in a bulk packs of ten (10), single-use foil pouches. Each foil pouch contains a 3 mL glass syringe of PHOTREXA VISCOUS or PHOTREXA contained within a Tyvek pouch.Bulk packs and kits should be stored at 15°-25°C (59°-77°F) and care should be taken to minimize exposure of the syringe to light once removed from its protective packaging. Discard syringe after use.For topical ophthalmic use.PHOTREXA VISCOUS and PHOTREXA should be used with the KXL System only.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
None.

Large doses of naloxone are required to antagonize buprenorphine since the latter has a long duration of action due to its slow rate of binding and subsequent slow dissociation from the opioid receptor. Buprenorphine antagonism is characterized by a gradual onset of the reversal effects and a decreased duration of action of the normally prolonged respiratory depression. The barbiturate methohexital appears to block the acute onset of withdrawal symptoms induced by naloxone in opiate addicts.

Ulcerative keratitis can occur. Monitor for resolution of epithelial defects. [].

The following clinically significant adverse reactions are described elsewhere in the labeling:

Ulcerative keratitis [ ()]

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).